Archives April 2011

Each blister pack contained 5 vials of serum. Two machines were equipped with 2 In-Sight cameras. The vials passed along a conveyor where they were inspected by the cameras. In-Sight uses PatMax™, the powerful Cognex vision tool for part finding and localization to locate the units of serum so each individual vial can be inspected for impurities. Any impurities detected result in the rejection of the pack. All inspected vials were sent for packaging. The vision solution was fully integrated into the company's quality management system. The user friendly development environment in In-Sight Explorer proved beneficial, allowing a convenient user interface for programming vision tasks in addition to benefits such as • Speed -10,000 bottles inspected per hour • Elimination of defects reliably at high speed • No false rejects • Ease of use After having worked with different vision suppliers, IPF chose Cognex vision systems for their robustness under more...

The Himalaya Drug Company, one of India's leading companies on herbal health has launched Liv.52 HB, the first herbal drug for the effective management of Hepatitis B Virus (HBV) infection. The drug is an US patent-pending phytopharmaceutical formulation that is recommended for the treatment of HBV infection. Liv.52 HB exerts antiviral activity and   enhances   the   antioxidant defense system. "Available   treatments,   while effective,   come   with   serious side-effects and are very costly. Clinical studies on Liv. 52 HB have revealed that the efficacy rate is comparable to that of currentavailabletreatmentswithoutanyside-effects.evenafterlong-termadministration. Moreover, the entire cost of six-month treatment with Liv.52 HB comes to just Rs.4, 680," said Philipe Haydon, CEO, Pharmaceutical Division, the Himalaya Drug Company.

Freeman Technology has launched the FT4 Powder Rheometer, which is a new version of software for the company's established universal powder tester. The new Powder Rheometer software introduces a completely redesigned graphical user interface providing a clearer look and improving the display of real-time test information. It has the flexibility to deliver systematic guidance to new users, while giving experienced operators the ability to develop and run bespoke methodologies. The new interface gives complete access to the full shear, dynamic and axial powder testing capabilities of the FT4, allowing users to build a comprehensive behavioural profile of a powder by drawing in results from each test methodologies. The FT4 Powder Rheometer is a universal powder tester that uses patented dynamic methodology, fully automated shear cells and several bulk property tests, including density, compressibility and permeability to quantify powder properties in terms of flow and process ability.

In the world of mixed identities and subsequent ambiguities, the essence of a noble concept like Continuing Medical Education (CME) by pharma companies seems diluted. In doubt is the intention 'is it crystal clear'/ ie, imparting up to-date medical education such that the professionals can keep themselves abreast with the growth in market, or 'is it one of the innovative and strategic tools for marketing'? Experts share their views and opinions.  Chandreyee Bhaumik  Knowledge without justice ought to be called cunning rather than wisdom. –Pato When pharma companies are organizing CME programmes, several in the industry are observing this action as a cunning move rather than one meant for mere knowledge-imparting purpose. By definition, CME refers to a specific form of Continuing Education (CE) that helps those in the medical field to maintain competence and learn about new & developing areas of their field. These activities may take place as more...

With a wide range of exhibitors,   participants and visitors, Pharma Tech Expo 2011 a three-day event made its debut in the state of Madhya Pradesh. The state shares its boundary with the adjoining pharma hubs Maharashtra, Gujarai and Goa, "The    Indian    pharmaceutical industry is witnessing a spectacular growth phase and Madhya Pradesh, the second largest Indian state, led by Indore is increasingly becoming a  part  of  this  growth  story. The Indian pharma market is likely to undergo a major transformation and  is  expected to  rise  from present  size of Rs.100,000  crore (S21  billion)  to Rs.225,000 crore (S50 billion) by 2020, remarked N R Munjal, President – Indian Drug Manufacturers' Association (IDMA), Vice   Chairman   -   Pharmexcil, Vice   Chairman   and   Managing Director, and - Swift Laboratories Ltd, at the debut of Pharma Tech Expo that was held during April 22-24, 2011, at Indore, Madhya Pradesh. The expo was jointly organized by Pharma more...

Depression can be due to various reasons- They need not always be due to physical reasons. Often the mind is affected due to various stresses and the morale comes down. This further leads to defeatism and negative thinking. If the mind is affected for a long time, the health is also affected in the viscious circle. The normal method to combat depression is by taking antidepressants regularly. It has now been studied by taking samples of twins that regular use of antidepressants increases the wall-thickness of the arteries. The inner lining of the carotid artery which carries oxygen to the brain is definitely increased in thickness by these medicines. The association between intake of antidepressants and the increase in the intima-media thickness (IMT) has been well established. This leads to the increase in the risk of heart attack .and strokes. Finally, starting from the treatment of depression, one is led more...

Cord Life India, life Asia's largest stemcell bank, saved the life of five-year old Moinam from Siliguri who was suffering from ebeta thalassemia since he was five months old. The bank had preserved the cord blood of Moinam's sister and provided it to Moinam at the time of the transplant therapy. The stemcell transplant from cordblood and bone marrow gave him a new life and the transplant also became India's first successful mixed stemcell transplant. Dr Ashis Mukherjee at the Netaji Subhash Cancer Research Institute carried out the stem cell transplantation and this is the first time that a mixed stem cell transplant has been performed in India. Dr. Prosanto Chowdhury, Medical Director, CordLife India, said, "When stem cells are needed to treat a life-threatening disease, doctors can effectively predict transplant success by evaluating two factors - HLA compatibility and stem cell count. Transplants like these confirm CordLife's technology and more...

Cole-Farmer, a leading global source of laboratory and industrial fluid handling products, instrumentation, equipment and supplies has received the exclusive rights to sell the picoSpin™ Beachtop NMR Spectrometer, internationally. This product of picoSpin, LLC is an innovative and disruptive technology that ' combines low price and a compact footprint, with true spectroscopic capability, with this combination of sought-after features, research labs and educators now have affordable access to a dedicated NMR spectrometer. John Price, PhD, President and Chief Scientist of picoSpin, LLC, said, "You can now have an NMR system right at your lab bench- You can deploy multiple unils , within a factory to continuously monitor process fluids and control them all from a web browser anywhere in the world." The new device is a complete liquid-phase proton NMR system, including permanent magnet, transmitter, receiver, data acquisition, programmable pulse sequencer, ethernet interface and intuitive web-based control software. .As a more...

Cadila Healthcare, Ars. Rs. 4450 crore plus pharma major from Ahmadabad, has recorded impressive  Financia share performance during the year ended March 2011, on account of higher formulation export and domestic business, new products launch and strategic pact with Abbott Laboratories. The consolidated net profit has taken a quantum jump of 40.8 percent and touched to Rs. 711 crore from 505 crore in the previous year. Its consolidated net sales moved up by 24.9 percent to Rs. 4,465 crore from Rs. 3,574 crore. Further, the board of directors has recommended higher equity dividend of 125 percent (Rs. 6.25 Per share of Rs. 5 each) for the year 2010-11 as compared to 100 per cent in the previous year. The earnings per share worked out to Rs. 34.73 as against Rs. 24.67 in the last year. The company's formulation exports was buoyed by 44 percent growth in sales in the US more...

Biocon has delivered strong multi- Sector growth for the financial year 2011. Commenting on the results, Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon, stated, "Emerging markets have realized significant and sustained growth for our Active Pharmaceutical Ingredients (APIs), whilst our branded formulations have scripted business success in the Indian market place. Licensing income from Pfizer and others has contributed materially to profit generation this fiscal. Our research services businesses supported by Syngene and Clinigene have signaled a turn around. We are confident this will drive robust profitability next fiscal. To support our expanding business operations, we expect to increase our employee strength by around 1000 in FY12.1 am pleased to announce the payment of an interim dividend of RS. 1.50 Per share and recommend a final dividend of RS. 3.00 per equity share as our on-going commitment to building incremental shareholder value. “The total annual income of Biocon group has more...


Archive



You need to login to perform this action.
You will be redirected in 3 sec spinner